[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anisometropia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anisometropia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,66,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100652964","children-receiving-monocular-misight-1-day-treatment-for-unilateral-myopia-100652964",false,"NCT07778264","Children Receiving Monocular MiSight® 1 Day Treatment for Unilateral Myopia","Natural History and Post-Conversion Clinical Outcomes of the Fellow Eye in Children Receiving Monocular MiSight® 1 Day Treatment for Unilateral Myopia: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Age 7-18 years.\n2. Cycloplegic SER ≤ -0.75 D in one eye and \\> -0.50 D in the fellow eye.\n3. Cylinder ≤1.00 D in the myopic eye.\n4. BCVA ≥20\u002F25 (0.1 logMAR).\n5. Willingness to wear MiSight® 1 Day for ≥10 hours\u002Fday and ≥6 days\u002Fweek.\n6. Willingness of the participant and parents to comply with the study procedures and complete 12 months of follow-up.\n7. Written informed consent provided by the legal guardian.\n\nExclusion Criteria:\n\n* Previous orthokeratology treatment.\n* Previous atropine treatment exceeding one month.\n* Previous use of other myopia-control soft contact lenses.\n* Keratoconus, corneal degeneration, or other corneal disease.\n* Amblyopia, strabismus, or other significant binocular visual dysfunction.\n* Cataract, glaucoma, uveitis, retinal disease, or other significant ocular disease.\n* Systemic connective-tissue or neurological disease affecting vision.\n* Known allergy to atropine or contact lens materials.\n* Inability to comply with scheduled visits or anticipated relocation during the study period.","ALL","7 Years","18 Years",{"count":20,"type":21},100,"ESTIMATED","100 Months","OBSERVATIONAL","This investigator-initiated prospective observational cohort study aims to establish the first longitudinal clinical database evaluating fellow-eye myopia development in children receiving monocular MiSight® 1 Day treatment for unilateral myopia.\n\nAll myopic eyes will receive MiSight® 1 Day as standard clinical care, while the fellow eye will undergo regular observation without prophylactic intervention. If the fellow eye develops myopia (cycloplegic spherical equivalent ≤ -0.50 D), standard myopia control treatment, including MiSight® 1 Day or 0.05% atropine ophthalmic solution, will be initiated according to routine clinical practice and shared decision-making between the investigator and the child's parents The findings are expected to provide important evidence regarding fellow-eye refractive development, identify predictors of myopia conversion, optimize the timing of intervention, and support personalized myopia management in children with unilateral myopia.",[26,27],"Myopia (Disorder)","Anisometropia","NOT_YET_RECRUITING","2026-08-18",{"date":31,"type":32},"2026-08-21","ACTUAL",{"date":34,"type":21},"2026-09-15",{"date":36,"type":21},"2029-12-31",{"name":38,"class":39},"Buddhist Tzu Chi General Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100651593","a-randomized-controlled-trial-of-gabor-based-perceptual-learning-for-adult-amblyopia-100651593","NCT07764198","A Randomized Controlled Trial of Gabor-Based Perceptual Learning for Adult Amblyopia","Inclusion Criteria\n\n1. Written informed consent; age 18-39 years inclusive at randomization.\n2. Diagnosis of amblyopia, with amblyopic-eye BCVA of approximately 20-70 ETDRS letters (approximately decimal BCVA 0.05-0.6).\n3. Amblyopia caused by anisometropia, strabismus, or both, meeting the following definitions:\n\n   Anisometropic amblyopia: interocular spherical-equivalent difference ≥1.00 D or astigmatic difference ≥1.50 D in any meridian, with no manifest strabismus at distance or near.\n\n   Strabismic amblyopia: strabismus at distance or near, or a history of strabismus surgery, without meeting the anisometropia criterion.\n\n   Combined-mechanism amblyopia: meeting both the strabismus and anisometropia criteria.\n4. Completion of standardized optical correction and the 8-12-week stability period; absolute difference between week -4 and week 0 ETDRS scores \\\u003C5 letters, with no continuing pretreatment improvement trend.\n5. Ability to use the study device for home training and accept electronic adherence monitoring.\n\nExclusion Criteria\n\n1. Eccentric fixation, clinically significant nystagmus, or inability to complete reliable ETDRS testing.\n2. Corneal, lenticular, retinal, macular, optic-nerve, or neurologic disease capable of explaining the visual-acuity reduction.\n3. Study-eye spherical equivalent \\\u003C-8.00 D, or high refractive error judged by the investigator to compromise test reliability.\n4. Recent intraocular surgery or ocular trauma, or extraocular-muscle surgery considered likely to affect outcomes.\n5. Diplopia at baseline that interferes with safety evaluation, or an unacceptable training risk as judged by the investigator.\n6. Patching, penalization, other visual training, or treatment likely to affect amblyopia outcomes within the prespecified period before randomization.\n7. Inability to complete follow-up, understand the tasks, or participation in another clinical study likely to affect outcomes.","39 Years",{"count":48,"type":21},80,"INTERVENTIONAL",[51],"NA","This study is initiated and conducted by the Shanghai Eye Disease Prevention and Treatment Center \u002F Shanghai Eye Hospital. Many people once believed that amblyopia (commonly known as \"lazy eye\") could only be treated during childhood (the critical period of visual development) and that nothing could be done once we reached adulthood. However, modern visual science research has revealed that the adult visual cortex still retains a certain degree of \"neuroplasticity\" (the brain's ability to reorganize, learn, and adapt). The Gabor target training used in this study-powered by RevitalVision software-is a scientifically proven visual training program. By repeatedly performing visual tasks near your perception threshold on a computer screen, this training exercises your eye-brain coordination, helping your brain process visual information much more efficiently.\n\nTo help you and your family participate with peace of mind, we have compiled the following answers to frequently asked questions:\n\nQ1: How will I participate in this study? What is the difference between the two groups?\n\nTo scientifically compare the training's effectiveness, this study uses a rigorous randomized controlled design. A total of 80 eligible participants will be randomly assigned by a computer program in a 1:1 ratio to one of two groups:\n\nImmediate Training Group:\n\nYou will begin the 12-week home-based Gabor visual training right after randomization. Your study participation ends after your Week 12 follow-up.\n\nDelayed Training Group:\n\nDuring the first 12 weeks after randomization, you will simply wear your prescribed glasses and go about your daily life without active visual training.\n\nAfter completing your Week 12 eye evaluation, you will receive the exact same 12-week Gabor visual training for free (conducted from Week 12 to Week 24).\n\nPlease be assured: No matter which group you are assigned to, every eligible participant will ultimately receive the exact same 12-week professional visual training. This \"delayed treatment\" design is highly ethical. It ensures everyone gets treated while allowing us to compare the two groups transitionally during the first 12 weeks, thereby ruling out other factors like \"getting used to the vision charts\" or \"gradually adjusting to new glasses\".\n\nQ2: How is the visual training performed? Is it difficult to do at home?\n\nThe training is fully home-based, meaning you do not need to visit the hospital constantly. However, it requires your dedication and, ideally, supervision from your family:\n\nTraining Tools: You will use the specialized RevitalVision perceptual learning software on a calibrated computer monitor.\n\nTraining Environment: The training should be done in a dark or standard low-light room. Your only main light source should be the computer screen, and you will sit exactly 1.5 meters away.\n\nGlasses \\& Patching: You must wear your prescribed study glasses during training. If you have monocular (one-sided) amblyopia, you will need to patch your stronger eye (non-study eye), using only your weaker eye (amblyopia eye) to view the screen.\n\nFrequency \\& Duration: You will train 4 times a week, for about 30 minutes per session, over a continuous span of 12 weeks. The software is adaptive: it automatically adjusts the difficulty of your next session based on your performance to keep you at your optimal training zone.\n\nQ3: What do I need to do at the hospital during the study?\n\nYour safety and visual health are our top priorities. We will provide meticulous, standardized eye examinations throughout the study:\n\nBefore the training begins, you will go through an 8- to 12-week \"Refractive Stability Phase\". During this time, we will perform cycloplegic refraction (dilation) and prescribe your glasses, checking your vision multiple times to ensure your baseline sight is completely stable.\n\nDuring the study, you will only need to visit the clinic for follow-ups at Weeks 6 and 12 (the Delayed Group will also have visits at Weeks 18 and 24).\n\nAt these visits, our examiners (who do not know which group you are in to ensure objectivity) will measure your vision using standard ETDRS charts, evaluate your contrast sensitivity (using the computerized FrACT test), assess your stereoacuity (3D vision), and capture advanced 3D structural scans of your retina and choroid using Swept-Source OCT.\n\nQ4: Is the training safe? What if my vision gets worse? The visual training is entirely physical and non-invasive, with an excellent safety record.\n\nIn very rare cases, some participants might experience mild, temporary eye strain, headaches, or slight discomfort when they first start training.\n\nDouble-Safety \\& Rescue Protocols: We have set strict \"rescue criteria\". If at any point during your observation or training, your vision drops significantly or if you experience persistent double vision, we will immediately initiate a professional assessment. If necessary, we will halt the training and provide standard clinical medical care.",[54,27],"Amblyopia","RECRUITING","2026-08-09",{"date":58,"type":32},"2026-08-13",{"date":60,"type":32},"2025-05-25",{"date":62,"type":21},"2026-12",{"name":64,"class":39},"Jiannan Huang",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":49,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":65},"100633935","targeted-lens-intervention-for-myopic-anisometropia-in-children-100633935","NCT07533149","Targeted Lens Intervention for Myopic Anisometropia in Children","Clinical Investigation of Targeted Lens Intervention in the Management of Myopic Anisometropia in Children","Inclusion Criteria:\n\n1. Voluntary\n2. Informed consent of parent\u002Fguardian and assent of participant\n3. Age equal to or greater than 6 years old and less than 13 years at the time of signing informed consent and assent\n4. SER equal or less than -0.50 D and equal or greater than .5.00 D with astigmatism not more than 2.50 D\n5. Difference in SER (anisometropia) between two eyes .1.00 D\n6. Best corrected visual acuity (BCVA) better than or equal to +0.20 LogMAR in each eye\n7. Agree to wear study spectacles for .12 hours\u002Fday and 7 days\u002Fweek\n8. Willingness and ability to participate in investigation for 12 months and attend scheduled visits punctually\n9. Agree for no concurrent involvement in other myopia control treatment\n\nExclusion Criteria:\n\n1. History or presence of an ocular disease affecting refractive status\n2. History or presence of strabismus\n3. Presence of amblyopia\n4. Current or previous use of atropine and\u002For orthokeratology\n5. Known allergy to cycloplegic agents\n6. Contraindication to cycloplegic agents\n7. Cognitive or psychological vulnerability","6 Years","13 Years",{"count":76,"type":21},20,[51],"The goal of this clinical trial is to learn if our research spectacles will lower the difference in prescription (spectacles degree) between the eyes in children between 6 to 13 years old with anisometropic myopia. Anisometropic myopia is when the difference in myopia prescription between the two eyes are more than 1 diopter. The main question it aims to answer is:\n\n* How the eye responds to the research spectacles over time by measuring:\n\n  1. Change in axial length: the physical length of the eye from front to back.\n  2. Change in cycloplegic spherical equivalent refraction: an accurate measurement of the eye's prescription taken while the focusing muscles are temporarily relaxed with eye drops.\n\n     Participants will:\n* Wear the study spectacles\n* Visit Essilor R\\&D Centre and an eye clinic for follow-up sessions",[27,80],"Myopia",[82,83,84,85],"myopia control","anisometropia","axial length","spherical equivalent refraction","2026-04-09",{"date":88,"type":32},"2026-04-16",{"date":90,"type":21},"2026-04",{"date":92,"type":21},"2027-07",{"name":94,"class":95},"Essilor International","INDUSTRY",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":73,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":49,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":117,"leadSponsor":119,"locationsCount":65},"100603931","effect-of-light-blocking-lenses-on-hyperopic-anisometropic-children-100603931","NCT07142928","Effect of Light-Blocking Lenses on Hyperopic Anisometropic Children","A Prospective Randomized Controlled Trial on the Effect of Light-Blocking Lenses on Emmetropization in Hyperopic Anisometropic Children","Inclusion Criteria:\n\n* Aged 6 years or older and 12 years or younger;\n* The more hyperopic eye has a spherical refractive error between +3.0 D and +7.5 D; the less hyperopic eye has a spherical refractive error of at least +2.0 D; cylindrical refractive error between -2.0 D and 0 D; interocular difference in spherical power \\>=1.5 D and in cylindrical power \\\u003C=1.0 D;\n* Best-corrected visual acuity of 0.0 logMAR or better in both eyes;\n* Ocular deviation with spectacles less than 10 prism diopters;\n* Has been wearing standard single-vision spectacles regularly for more than six months;\n* In good general health, capable of receiving the study intervention, and willing to comply with the study protocol;\n* Written informed consent obtained from both the parent\u002Fguardian and the child, with agreement to comply with all study procedures and maintain follow-up availability throughout the study period;\n\nExclusion Criteria:\n\n* History of ocular trauma or eye surgery;\n* Presence of pathological abnormalities on anterior or posterior segment examination, or a history of organic ocular diseases such as cataract, glaucoma, corneal disease, or fundus disorders;\n* Intraocular pressure greater than 21 mmHg;\n* Presence of systemic diseases or other conditions deemed unsuitable for study participation;\n* Any other condition deemed inappropriate for participation in the clinical trial by the investigator;","12 Years",{"count":105,"type":21},90,[51],"To evaluate the effectiveness of light-blocking lenses in promoting emmetropization and reducing anisometropia in children with hyperopic anisometropia, and to assess the impact of light-intercepting lenses on visual function in this population.",[27,109],"Hyperopia",[27,109,111,112],"light-blocking lenses","emmetropization","2025-08-25",{"date":115,"type":32},"2025-08-27",{"date":113,"type":21},{"date":118,"type":21},"2027-06-30",{"name":120,"class":39},"Zhongshan Ophthalmic Center, Sun Yat-sen University"]